


Arthur Z. Schwartzbard, M.D., F.A.C.C.

Associate Professor of Medicine
NYU Grossman School of Medicine
Cardiology Attending
Department of Medicine
NYU Langone Medical Center
Faculty Practice Offices
530 First Ave, Suite HCC 5
New York, NY 10016
Tel: 212-263-0855
Fax: 646-501-0150



Clinical Training / Education

2015 – Present	Associate Professor
1997 – 2015	Assistant Professor NYU Langone Medical Center/Tisch & Kimmel Hospitals Faculty Practice Offices 530 First Ave, Suite HCC 5 New York, NY
1997 – Present	Attending Cardiologist Bellevue Hospital Center Cardiology Section 462 First Avenue New York, NY 10016
2003 – Present	Director of Clinical Lipid Research Center for the Prevention of Cardiovascular Disease NYU Langone Medical Center 530 First Ave, Suite HCC 5 New York, NY 10016 web: www.med.nyu.edu/cvprevention
2018 – Present	Director of the Preventive Cardiology Fellowship Program Center for the Prevention of Cardiovascular Disease NYU Langone Medical Center 435 East 30 th Street New York, NY 10016
1997 – 2014	Director, Non-invasive Cardiology Section Cardiology Section Department of Medicine New York Harbor Healthcare System, Manhattan Campus 423 East 23rd Street New York, NY 10016

1994 – 1997	Fellow in Cardiology NYU Medical Center/Bellevue Hospital Center, NY, NY
1993 – 1994	Chief Resident, Department of Medicine Hospital of the Albert Einstein College of Medicine
1991 – 1993	Resident, Department of Medicine
1990 – 1991	Intern, Department of Medicine Bronx Municipal Hospital Center, Bronx, NY
1986 – 1990	Sackler School of Medicine New York State/American Program Tel Aviv, Israel M.D. 1990
1985 – 1986	Rockefeller-University Research Labs Department of Biochemical Endocrinology Laboratory of Dr. Alan Saltiel New York, New York
1984 – 1985	Columbia College, Columbia University School of General Studies New York, New York Graduate courses, Basic sciences/Non-matriculating
1980 – 1984	Rutgers College, Rutgers University New Brunswick, New Jersey B.A. Biology 1984

License:

New York State: #188078
DEA: #BS52997228

Board Certification:

American Board of Internal Medicine: Internal Medicine 1993, 2009, 2020
Cardiovascular Disease 1997, 2007, 2017

Awards:

NYU Department Clinical Faculty Teaching Award 2011
NYU Cardiology Division: "Teacher of the Year" award 2001-2002
Genentech/American Heart Association Cardiovascular Meeting Grant 1996
Residency: Davidoff Award for Academic Excellence in Clinical Teaching 1991
Medical School: Dean's Award for Academic Excellence in the third year

Grants:

AHA Grant 2006- 2009 - Role of Thiazolidenedione in Insulin resistance and dyslipidemia.

Professional Memberships:

Member, American Heart Association

Fellow, American College of Cardiology

Journal Reviewer:

Atherosclerosis, Thrombosis, Vascular Biology 2007-Present
Cardiology 2007-Present
Circulation 2009-Present
Diabetes/Metabolism Research and Reviews 2009-Present
Digestive Diseases and Sciences 2009-Present
American Heart Journal 2011-Present
American Journal of Cardiology 2011-Present
Diabetes Care 2012-Present

Publications:

Textbook Chapters:

Tran, H, **Schwartzbard, A**, Underberg, J. Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients. In: Chapter 21 (pp. 399-413) Lipoproteins in Diabetes Mellitus. Alicia J. Jenkins, Peter P. Toth, Timothy J. Lyons, editors. Springer New York, 2014.

Fisher EA, **Schwartzbard AZ**. Familial Hypercholesterolemia. In: Clinical Genomics: Practical Applications in Adult Patient Care, 1e. Murray MF, Babyatsky MW, Giovanni MA, Alkuraya FS, Stewart DR, editors. McGraw-Hill New York, 2014.

Kliger C, **Schwartzbard A**, Fisher E, Weintraub H. Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. Chapter 11 (pp. 161-181) in Preventive Cardiology, Roger Blumenthal, JoAnne Foody, and Nathan Wong, editors. Published by Saunders, 2011.

Hong S, **Schwartzbard A**. Cardiac Complications of Urologic Surgery (p. 21-30). In Taneja et al. Complications of Urologic Surgery. Elsevier, Inc. 2009.

Katz ES, **Schwartzbard A**, Kronzon I. Anticoagulation in Dilated Cardiomyopathy, in Daniel WG, Kronzon I, Mugge A. Cardiogenic Embolism, Williams and Wilkins 1996.

Journal Publications:

McCarthy MM, Szerencsy A, Fletcher J, Taza-Rocano L, Weintraub H, Hopkins S, Applebaum R, **Schwartzbard A**, Mann D, D'Eramo Melkus G, Vorderstrasse A, Katz SD. The Impact of an Electronic Best Practice Advisory on Patients' Physical Activity and Cardiovascular Risk Profile. J Cardiovasc Nurs. 2023 Jul 14:10.1097/JCN.0000000000001021. doi: 10.1097/JCN.0000000000001021. Epub ahead of print. PMID: 37467192; PMCID: PMC10787798.

Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators (**Schwartzbard A**). Icosapent

Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. *Circulation*. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28. PMID: 34710343.

Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, Maldonado M, Liu CC, Liu J, Pong A, Cannon CP; VERTIS CV Investigators (**Schwartzbard A**). Ertugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial. *Clin J Am Soc Nephrol*. 2021 Sep;16(9):1345-1354. doi: 10.2215/CJN.01130121. Epub 2021 Jun 18. PMID: 34497110; PMCID: PMC8729577.

Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L; STABILITY Investigators (**Schwartzbard A**). Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. *JAMA Cardiol*. 2021 Dec 1;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079. PMID: 34431970; PMCID: PMC8387946.

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators (**Schwartzbard A**). Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. *N Engl J Med*. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. PMID: 32966714.

Dorcely B, Nitis J, **Schwartzbard A**, Newman JD, Goldberg IJ, Sum M. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet. *Curr Diabetes Rev*. 2021;17(2):243-246.

Wilcox, T., De Block, C., **Schwartzbard, A.Z.**, Newman, J.D. 'Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar'. *Journal of the American College of Cardiology*. 2020 75(16):1956-1974 (# 4402362)

Schwartzbard, AZ; Ahmad, Amier. 'Use of Inflammatory Biomarkers to Predict the Clinical Benefit of Ezetimibe: A Clinical Perspective'. *Journal of the American College of Cardiology*. 2019 74(8):1069-1070 (# 4047032) [Editorial]

Harkin, Nicole; Johnston, Emily; Mathews, Tony; Guo, Yu; **Schwartzbard, AZ**; Berger, Jeffrey; Gianos, Eugenia. 'Physicians' Dietary Knowledge, Attitudes, and Counseling Practices: The Experience of a Single Health Care Center at Changing the Landscape for Dietary Education'. *American journal of lifestyle medicine*. 2019 13(3):292-300 (# 3920212).

Newman, JD, Vani, AK, Aleman, JO, Weintraub, HS, Berger, JS; **Schwartzbard, AZ**. 'The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review'. *Journal of the American College of Cardiology*. 2018 72(15):1856-1869 (# 3329052)

Vani, A, **Schwartzbard, A**, Weintraub, HS. Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients with Nonobstructive Coronary Artery Disease. 4 Aug 2018. *Journal of the American Heart Association*. 2018;7:e010166

Rodriguez V, Newman JD, **Schwartzbard AZ**. 'Towards more specific treatment for diabetic dyslipidemia'. *Current opinion in lipidology*. 2018 (# 3144582)

Schwartzbard AZ, Newman JD, Weintraub HS, Baum SJ. 'The 2017 high blood pressure clinical practice guideline: The old and the new'. *Clinical cardiology*. 2018 41(3):279-281 (# 3011172)

Gianos E, Schoenthaler A, Guo Y, Zhong J, Weintraub H, **Schwartzbard A**, Underberg J, Schloss M, Newman JD, Heffron S, Fisher EA, Berger JS. Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial'. *American heart journal*. 2018 199(pp):37-43 (# 2968722).

Weiss MC, Berger J, Gianos E, Fisher E, **Schwartzbard A**, Underberg J, Weintraub H. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. *Journal of Clinical Lipidology*. 2017 Sep - Oct;11(5):1177-1180.

Rodriguez V, Weiss MC, Weintraub H, Goldberg IJ, **Schwartzbard A**. Cardiovascular Disease Leads to a New Algorithm for Diabetes Treatment *Journal of Clinical Lipidology*. *Journal of Clinical Lipidology*. 2017 Sep - Oct;11(5):1126-1133.

Newman J, **Schwartzbard AZ**, Weintraub H, Goldberg IJ, Berger JS. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. *Journal of the American College of Cardiology*. 2017 70(7):883-893.

Bangalore S, **Schwartzbard A**, Weintraub H, Gianos E, Ogedegbe O, Toklu B. Optimal Systolic Blood Pressure Target after SPRINT; Insights from a Network Meta-Analysis of Randomized Trials. *American Journal of Medicine*. 2017 Jun;130(6):707-719.

Newman JD, Rockman CB, Kosiborod M, Guo Y, Zhong H, Weintraub HS, **Schwartzbard AZ**, Adelman MA, Berger JS. Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease. *American Heart Journal*. 2017 184(pp):114-120.

Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, Goldberg I, **Schwartzbard AZ**. 'Cardiovascular Effects of the New Weight Loss Agents'. *J Am Coll Cardiol*. 2016 68(8):849-859.

Tanna MS, **Schwartzbard A**, Berger J, Underberg J, Gianos E, Weintraub H. 'Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?'. *Urologic Clinics of North America*. 2016 43(2):247-260.

Heffron S, Parikh A, Volodarskiy A, Ren-Fielding C, **Schwartzbard A**, Nicholson J, Bangalore S. Changes in Lipid Profile of Obese Patients following Contemporary Bariatric Surgery: A Meta-Analysis. *American Journal of Medicine*. 2016 Sep;129(9):952-9.

Balakrishnan R, Berger JS, Tully L, Vani, A, Shah, B, Burdowski, J, Fisher, E, **Schwartzbard, A**, Sedlis, S, Weintraub, H, Underberg, J, Danoff, A, Slater, J, Gianos, E. Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention. *Diabetes/Metabolism Research and Reviews*. 2015 Sep; 31(6): 603–609.

Tanna MS, **Schwartzbard A**, Berger JS, Alukal J, Weintraub H. The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?. *Current Atherosclerosis Reports*. 2015;17(3):490.

Shah B, Berger JS, Amoroso NS, Mai X, Lorin JD, Danoff A, **Schwartzbard A**, Lobach I, Guo Y, Feit F, Slater J, Attubato MJ, Sedlis SP. Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention. *American Journal of Cardiology*. 2014;113(9):1474-80.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; **Schwartzbard AZ** and SOLID-TIMI 52 Investigators, Steen DL. Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial (JAMA (2014) 312:10(1006-1015)). *JAMA*. 2014;- (# 4101712).

Alviar, CL, Kumar, V, Burdowski, J, Gianos, E, Berger, J, Balakrishnan, R, Vani, A, Guo, Y, Xu, J, Schwartzbard, A, Sedlis, S, Slater, J, Shah, B. Platelet Reactivity in Metabolic Syndrome: Relationship between Glycemic Control, Obesity, and On-treatment Platelet Reactivity. *Journal of the American College of Cardiology*. 2014 63:A1723-A1723

Shah B, Rockman CB, Guo Y, Chesner J, **Schwartzbard A**, Weintraub HS, Adelman MA, Riles TS, Berger JS. Diabetes and vascular disease in different arterial territories. *Diabetes Care*. 2014;37(6):1636-42.

Smilowitz NR, Donnino R, **Schwartzbard A**. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. *Circulation*. 2014;129(22):2305-12.

Tompkins R, **Schwartzbard A**, Gianos E, Fisher E, Weintraub H. A current approach to statin intolerance. *Clin Pharmacol Ther*. 2014;96(1):74-80.

Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, **Schwartzbard A**, Slater J, Stein R, Underberg J, Weintraub H, Fisher E, Berger J. Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. *American Heart Journal*. 2014;168(3):310-316.e3.

Axsom K, Berger JS, **Schwartzbard A**. Statins and diabetes: the good, the bad, and the unknown. *Curr Atheroscler Rep*. 2013;15(2):299.

Balakrishnan R, Berger J, Ullah O, Tully L, Vani A, **Schwartzbard A**, Weintraub H, Fisher E, Gianos E. Risk Factors Associated With Depression in Patients Undergoing Elective Percutaneous Coronary or Peripheral Intervention. *Circulation* 2013; 128.

Shah B, Rockman C, Chesner J, Guo Y, **Schwartzbard A**, Weintraub H, Adelman M, Riles T, Berger J. Association between diabetes mellitus and prevalence of vascular disease in different arterial territories. *Journal of the American College of Cardiology* 2013;61(10):E2050.

Singh A, Donnino R, Weintraub H, **Schwartzbard A**. Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events. *American Journal of Cardiology*. 2013;112(7):1033-8.

Singh A, Gianos E, **Schwartzbard A**, Black H, Weintraub H. Use of ambulatory blood pressure monitoring to guide hypertensive therapy. *Current Treatment Options in Cardiovascular Medicine*. 2013;15(6):746-60.

Singh A, **Schwartzbard A**, Gianos E, Berger JS, Weintraub H. What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. Current Treatment Options in Cardiovascular Medicine. 2013;15(1):104-17.

Ascunce RR, Berger JS, Weintraub HS, **Schwartzbard A**. The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Current Atherosclerosis Reports. 2012; 14: 167.

Choy-shan A, Zinn A, Shah B, Danoff A, Donnino R, **Schwartzbard A**, Lorin JD, Grossi E, Sedlis SP. Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. Coronary Artery Disease. 2012;23(5):354-8.

Donnino R, Patel S, Nguyen AH, Sedlis S, Babb JS, **Schwartzbard A**, Katz S, Srichai MB. Comparison of Quantity of Left Ventricular Scarring and Remodeling by Magnetic Resonance Imaging in Patients With versus Without Diabetes Mellitus and With Coronary Artery Disease. American Journal of Cardiology. 107,11,1575-1578; 2011.

Jacobson D, Tagoe C, **Schwartzbard A**, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. American Journal of Cardiology. 2011;108(3):440-4.

Newman B, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, **Schwartzbard A**, Kleinberg DL. Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function. The Journal of Clinical Endocrinology and Metabolism. 2011;96(1):122-32.

Tran HA, **Schwartzbard A**, Weintraub HS. Role of RAAS Inhibition in the Prevention of Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine. 2011;13(4):279-88.

Tran H, **Schwartzbard A**, Weintraub HS. Potential benefits of Aliskerin Beyond Blood Pressure Reduction. Cardiology In Review. 2011 Mar-April 19(2):90-94.

Weintraub HS, Tran H, Schwartzbard A. Potential benefits of aliskiren beyond blood pressure reduction. Cardiology in Review. 2011;19(2):90-4.

Reddy BM, Weintraub HS, **Schwartzbard A**. Ranolazine: A new approach to treating an old problem. Texas heart Inst J 2010; 37(6):641-7.

Weitz D, Weintraub H, Fisher E, **Schwartzbard A**. Fish Oil for the Treatment of Cardiovascular Disease. Cardiology in Review 2010; 18: 258-263.

Lala A, **Schwartzbard A**. Primary care management: Focus on Antiplatelet Therapy. Suppl Federal Practitioner, August 2010 Vo127 Suppl 7.

Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, **Schwartzbard A**. Fibrate therapy- an Update. Cardiology in Review 2008; 16: 129-141.

Zinn A., Felson S., Fisher E, **Schwartzbard A**. Reassessing the Cardiovascular Risks and Benefits of Thiazolidinediones. Clinical Cardiology. 2008;31(9):397-403.

Yatskar L, Holper E, Bansilal S, **Schwartzbard A**, Lombardero M, Ramanathan K, Feit F, Fisher E, Faxon D, Hochman JS, Farkouh ME. Long-term outcomes in non-diabetic patients with metabolic syndrome undergoing revascularization for multi-vessel coronary artery disease. *Atherosclerosis*. 2008; 198(2):389-95.

Shah B, Kumar N, Garg P, Kang E, Grossi E, Lorin J, **Schwartzbard A**, Mass H, Danoff A, Sedlis S. Metabolic Syndrome does not impact survival in patients treated for Coronary Artery Disease. *Coronary Artery Disease* 19(2):71-77, 2008.

Yatskar L., Fisher E., **Schwartzbard A**. Ezetimibe: Rationale and Role in the management of Hypercholesterolemia. *Clinical Cardiology*. 29, 52-55, 2006.

Patel R, **Schwartzbard A**, Bosco J, Torre P, Taneja SS. Renal tumor with associated venous tumor thrombus prolapsing through the tricuspid valve during diastole. *Urology*. 2005 Jul; 66(1): 195.

Spevack D.M., **Schwartzbard A**. B-Type Natriuretic Peptide Measurement in Heart failure. *Clin. Cardiology*. 2004; 27:498-494.

Yatskar, L, Holper, E, Lombardero, M, **Schwartzbard, A**, Ramanathan, K, Fisher, E, Feit, F. Impact of the metabolic syndrome on long-term mortality in patients with multi-vessel coronary artery disease undergoing revascularization. *Circulation*. 2004;110(17):118-118.

Lochow P, **Schwartzbard A**, Guest J, Ripps C, Matalon D, Gambetta R, Tunick PA, Sedlis S. Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma. *Angiology*. 2002;53(4):423-428

Schwartzbard A, Freedberg RS, Kronzon I. The Value of Repeat Transesophageal Echocardiography in the Evaluation of Embolism from the Aorta. *Journal of the American Society of Echocardiography*. 2000;13:1124-1126.

Katz ES, Tsiamtsiouris T, Applebaum RM, **Schwartzbard A**, Tunick PA, Kronzon I. Surgical Left Atrial Appendage Ligation is Frequently Incomplete: A Transesophageal Echocardiographic study. *J Am Coll Cardiol* 2000;36:468-471.

Schwartzbard A, Tunick PA, Rosenzweig BP, Kronzon I. The role of Transesophageal Echocardiography in the diagnosis and treatment of right atrial thrombi. *Journal of the American Society of Echocardiography*.. 1999; 12:64 - 9.

Schwartzbard A, Tunick PA, Kronzon I. Aortic-LA fistula: A complication of endocarditis. *Circulation* 1998; 98: 604.

Schwartzbard A, Kronzon I. The dynamic nature of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Congestive Heart Failure* Sept 1997, 14-21.

Kathuria, N, Koenig, K, **Schwartzbard, A**, Mele, KA, Levin, RI. Accelerated atherosclerosis in South Asian expatriates living in New York. *Journal of investigative medicine*. 1996;44(3):A312-A312.

Patel R, Lipper B, **Schwartzbard A**, Nelson C, O'Conner MA, Frishman W. Toxic effects of Diltiazem in a patient with chronic renal failure. J of Clinical Pharmacology 1994, 34 (3), 273 - 274.